Bosnia ja Hertsegoviina - horvaadi - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

salveo d.o.o. sarajevo - cineol - gastrorezistentna kapsula, meka - 200 mg/1 kapsula - 1 gastrorezistentna meka kapsula sadrži: 200 mg cineola

Bosnia ja Hertsegoviina - horvaadi - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

salveo d.o.o. sarajevo - cineol - gastrorezistentna kapsula, meka - 100 mg/1 mkapsula - 1 gastrorezistentna meka kapsula sadrži: 100 mg cineola

Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - klonazepam - tableta - 0,5 mg - urbroj: jedna tableta sadrži 0,5 mg klonazepama

Horvaatia - horvaadi - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - klonazepam - tableta - 2 mg - urbroj: jedna tableta sadrži 2 mg klonazepama

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatid - osteoporoza - homeostaza kalcija - movymia je indicirana kod odraslih osoba. liječenje osteoporoze u žena u postmenopauzi i muškaraca pri povećanom riziku od loma. u žena u postmenopauzi pokazano je značajno smanjenje učestalosti prijeloma kralješnjaka i ne-kralješaka, ali ne i fraktura kuka. liječenje osteoporoze, povezan sa stalnim sistemsku terapiju s glukokortikoidi, kod žena i muškaraca pod povećanim rizikom prijeloma.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Bosnia ja Hertsegoviina - horvaadi - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

alpen pharma d.o.o. - cardiospermum, galfimia Глаука diehl. d3, Д4 люффы operculata Трит. - tableta - 25 mg/1 tableta+ 25 mg/1 tableta+ 25 mg/1 tableta - jedna tableta sadrži: 25 mg luffa operculata trit. d4 25 mg galphimia glauca trit. d3 25 mg cardiospermum trit. d3

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

actavis group ptc ehf - oseltamivir - gripa, ljudska - antivirals for systemic use, neuraminidase inhibitors - liječenje influenzain bolesnika u dobi od jedne godine i starijih, kod kojih je tipični simptomi gripe, kada je virus gripe kruži u društvu. ebilfumin je indiciran za liječenje djece u dobi do 1 godine u vrijeme izbijanja pandemije gripe (vidi odjeljak 5. 2 od Смпц). liječnik mora uzeti u obzir патогенность kruži soja i osnovne bolesti pacijenta, da li postoji potencijalna korist za dijete. prevencija influenzapost preventivne mjere kod osoba s 1 godine i stariji nakon kontakta s klinički диагностированный slučaj gripe, kada je virus gripe kruži u društvu. pravilno korištenje ebilfumin za prevenciju gripe treba utvrditi u svakom konkretnom slučaju, s obzirom na okolnosti i stanovništva koje trebaju zaštitu. u iznimnim situacijama (e. u slučaju neusklađenosti između циркулирующим i вакцинных sojeva virusa, i u slučaju pojave pandemije) sezonska prevencija može se vidjeti kod osoba u dobi od jedne godine i stariji. ebilfumin indiciran za постконтактной prevenciju influence u dojenčadi manje od 1 godine, u vrijeme izbijanja pandemije gripe (vidi odjeljak 5. 2 od Смпц). ebilfumin nije zamjena za cijepljenje protiv gripe .